Atai Life Sciences N.V. (ATAI)
Atai Life Sciences Statistics
Share Statistics
Atai Life Sciences has 198.31M shares outstanding. The number of shares has increased by 1.08% in one year.
| Shares Outstanding | 198.31M |
| Shares Change (YoY) | 1.08% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 9.03% |
| Shares Floating | 135.18M |
| Failed to Deliver (FTD) Shares | 3.5K |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 11.55M, so 6.88% of the outstanding shares have been sold short.
| Short Interest | 11.55M |
| Short % of Shares Out | 6.88% |
| Short % of Float | 9.87% |
| Short Ratio (days to cover) | 6.15 |
Valuation Ratios
The PE ratio is -1.43 and the forward PE ratio is -2.19. Atai Life Sciences's PEG ratio is -0.01.
| PE Ratio | -1.43 |
| Forward PE | -2.19 |
| PS Ratio | 691.6 |
| Forward PS | 0.6 |
| PB Ratio | 1.83 |
| P/FCF Ratio | -2.58 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Atai Life Sciences N.V. has an Enterprise Value (EV) of 195.4M.
| EV / Earnings | -1.31 |
| EV / Sales | 634.41 |
| EV / EBITDA | -1.35 |
| EV / EBIT | -1.9 |
| EV / FCF | -2.37 |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.21 |
| Quick Ratio | 3.21 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.12 |
| Cash Flow / Debt | -10.87 |
| Interest Coverage | -32.87 |
Financial Efficiency
Return on equity (ROE) is -1.28% and return on capital (ROIC) is -82.92%.
| Return on Equity (ROE) | -1.28% |
| Return on Assets (ROA) | -0.94% |
| Return on Capital (ROIC) | -82.92% |
| Revenue Per Employee | $5,703.7 |
| Profits Per Employee | $-2,764,240.74 |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 356K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -25.38% in the last 52 weeks. The beta is 1.19, so Atai Life Sciences's price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | -25.38% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.44 |
| Relative Strength Index (RSI) | 45.3 |
| Average Volume (20 Days) | 2.9M |
Income Statement
In the last 12 months, Atai Life Sciences had revenue of 308K and earned -149.27M in profits. Earnings per share was -0.93.
| Revenue | 308K |
| Gross Profit | 308K |
| Operating Income | -102.69M |
| Net Income | -149.27M |
| EBITDA | -144.81M |
| EBIT | -102.69M |
| Earnings Per Share (EPS) | -0.93 |
Balance Sheet
The company has 17.5M in cash and 7.58M in debt, giving a net cash position of 9.92M.
| Cash & Cash Equivalents | 17.5M |
| Total Debt | 7.58M |
| Net Cash | 9.92M |
| Retained Earnings | -700.21M |
| Total Assets | 159.39M |
| Working Capital | 55.17M |
Cash Flow
In the last 12 months, operating cash flow was -82.44M and capital expenditures 0, giving a free cash flow of -82.44M.
| Operating Cash Flow | -82.44M |
| Capital Expenditures | 0 |
| Free Cash Flow | -82.44M |
| FCF Per Share | -0.51 |
Margins
Gross margin is 100%, with operating and profit margins of -33.34K% and -48.46K%.
| Gross Margin | 100% |
| Operating Margin | -33.34K% |
| Pretax Margin | -48.18K% |
| Profit Margin | -48.46K% |
| EBITDA Margin | -47.02K% |
| EBIT Margin | -33.34K% |
| FCF Margin | -26.77K% |
Dividends & Yields
ATAI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -63.27% |
| FCF Yield | -28.38% |
Analyst Forecast
The average price target for ATAI is $10, which is 580.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 580.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -4.67 |
| Piotroski F-Score | 4 |